Ars Pharmaceuticals, INC Schedule 13D activist filings

ARS Pharmaceuticals, Inc. has entered into a credit agreement for up to $250 million in term loans with RA Capital affiliates and OMERS Administration Corporation to fund product development and general corporate purposes.

Deerfield Management and its affiliated funds have reduced their beneficial ownership in ARS Pharmaceuticals, Inc. to 7.75% through recent open market sales.

Deerfield Private Design Funds have substantially decreased their beneficial ownership in ARS Pharmaceuticals, Inc. through a series of open market sales in July 2025.

Deerfield Management Company and its affiliated funds have reduced their beneficial ownership in ARS Pharmaceuticals, Inc. to 9.90% of common stock through recent open market sales.

Deerfield Management Company, L.P. and its affiliated funds, along with James E. Flynn, have filed an Amendment No. 2 to Schedule 13D, reporting a collective beneficial ownership of 10.72% of ARS Pharmaceuticals, Inc.'s common stock.